Clinical Trials on HER2+ Early or Locally Advanced Breast Cancer in Canada
Total 199 results
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Hoffmann-La RocheActive, not recruitingInflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast CancerCanada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Ontario Clinical Oncology Group (OCOG)Juravinski Cancer Centre FoundationCompleted
-
Sunnybrook Health Sciences CentreCompletedLocally Advanced Breast CancerCanada
-
Ontario Clinical Oncology Group (OCOG)Completed
-
University Health Network, TorontoCompletedBreast Cancer | Locally Advanced Breast CancerCanada
-
Lawson Health Research InstituteRecruitingLocally Advanced Breast Cancer | High-Risk CancerCanada
-
Sermonix Pharmaceuticals Inc.Linical Accelovance GroupActive, not recruitingLocally Advanced or Metastatic Breast CancerUnited States, Canada, Israel
-
AstraZenecaRecruitingLocally Advanced (Inoperable) or Metastatic Breast CancerSpain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Brazil, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Poland, Sweden, Italy
-
Hoffmann-La RocheRecruitingLocally Advanced or Metastatic Breast CancerFrance, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
-
AstraZenecaDaiichi SankyoActive, not recruitingBreast Cancer | Breast Neoplasms | HER2-positive Early Breast CancerUnited States, Italy, Spain, Poland, Taiwan, Thailand, Canada, Germany, Korea, Republic of, Brazil, India, Japan, Peru, Philippines, China, Saudi Arabia, Russian Federation, Bulgaria
-
Gilead SciencesRecruitingStage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast CancerTaiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
-
Hoffmann-La RocheCompletedHER2-Positive Early Breast CancerUnited States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
AstraZenecaDaiichi SankyoNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerCanada
-
AstraZenecaActive, not recruitingLocally Advanced (Inoperable) or Metastatic Breast CancerUnited States, Italy, Spain, Belgium, Hungary, Poland, Canada, France, Germany, Korea, Republic of, Japan, Peru, Russian Federation, United Kingdom, China, Taiwan, Israel, Australia, Argentina
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedAdvanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)United States, Belgium, Canada, Italy, Spain, United Kingdom
-
Spanish Breast Cancer Research GroupPierre Fabre Laboratories; Puma Biotechnology, Inc.RecruitingHER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast CancerSpain
-
Novartis PharmaceuticalsCompletedHR+ HER2- Men, Pre/Postmenopausal Advanced Breast CancerCanada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada, Spain
-
Puma Biotechnology, Inc.CompletedEarly Stage HER2+ Breast CancerSpain, United States, France, Australia, Germany, Austria, Canada
-
AstraZenecaActive, not recruitingAdvanced ER-Positive HER2-Negative Breast CancerUnited States, Italy, Spain, Belgium, Poland, Canada, Germany, Korea, Republic of, Russian Federation, France, Israel, Hungary, Portugal, United Kingdom, Georgia, Ukraine
-
AstraZenecaCompletedMetastatic Breast Cancer | Locally Advanced Breast CancerSweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, H...
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Ottawa Hospital Research InstituteCompletedEarly-stage Breast CancerCanada
-
Ottawa Hospital Research InstituteActive, not recruitingEarly-stage Breast CancerCanada
-
Juravinski Cancer CenterCompletedEarly Stage Breast CancerCanada
-
PrecirixTerminatedAdvanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care TreatmentUnited States, Canada
-
University Health Network, TorontoRecruitingBreast Cancer | HER2-positive Breast CancerCanada
-
British Columbia Cancer AgencyActive, not recruitingEarly Stage Breast CancerCanada
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Sunnybrook Health Sciences CentreSeagen Inc.; Biocon BiologicsRecruitingHER2-positive Breast Cancer | LMDCanada
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
-
Ottawa Hospital Research InstituteRecruiting
-
AstraZenecaActive, not recruitingLocally Advanced or Metastatic Solid TumoursUnited States, Spain, Canada, Korea, Republic of
-
Ottawa Hospital Research InstituteActive, not recruiting
-
Fudan UniversityNot yet recruitingNeoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast CancerChina
-
TakedaTakeda Development Center Americas, Inc.RecruitingUnresectable Locally Advanced or Metastatic CancerSpain, United States, Australia, Canada
-
Seagen Inc.CompletedHER2 Positive Breast CancersUnited States, Canada
-
University Health Network, TorontoActive, not recruitingBreast Cancer | Advanced Solid CancersCanada
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR T790M+ NSCLCCanada, Korea, Republic of, Taiwan
-
Ontario Clinical Oncology Group (OCOG)University Health Network, Toronto; Princess Margaret Hospital, CanadaCompleted
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Unresectable Breast Carcinoma | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States, Canada